
    
      The primary objective is to differentiate the clinical utility of Prospera testing from the
      use of creatinine testing as measured by the proportion of positive biopsies in post renal
      allograft patients.

      Secondary objectives include:

        -  To observe the performance of the Prospera assay in detecting AR (repeated validation)

        -  To evaluate whether Prospera can detect AR earlier and more often than SCr

        -  To determine whether use of Prospera will significant decrease the overall number of
           surveillance biopsies when compared to routine SCr surveillance
    
  